ストックスクリーナーアプリを入手
4.27
2.03%
0.085
前日終値:
$4.185
開ける：
$4.17
24時間の取引高:
1,962
Relative Volume:
0.17
時価総額：
$12.86M
収益：
$37.20M
当期純損益:
$-11.85M
株価収益率:
-22.38
EPS:
-0.1908
ネットキャッシュフロー:
$-10.59M
1週間 パフォーマンス:
-2.51%
1か月 パフォーマンス:
-44.37%
6か月 パフォーマンス:
-63.38%
1年 パフォーマンス:
-78.32%
1日の値動き範囲:
$4.08
$4.29
1週間の範囲:
$3.765
$4.565
52週間の値動き範囲:
$3.765
$20.40
Cytosorbents Corp Stock (CTSO) Company Profile
Compare CTSO vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
4.08 | 13.80M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
96.46 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.90 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.08 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.70 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.38 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-07 | 開始されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2020-09-17 | 開始されました | Jefferies | Buy |
| 2020-09-01 | 開始されました | SVB Leerink | Outperform |
| 2017-08-08 | 繰り返されました | Maxim Group | Buy |
| 2016-10-26 | 開始されました | Aegis Capital | Buy |
| 2016-05-24 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 繰り返されました | MLV & Co | Buy |
| 2015-04-01 | 繰り返されました | MLV & Co | Buy |
| 2015-03-05 | 開始されました | MLV & Co | Buy |
| 2015-02-25 | 開始されました | WBB Securities | Speculative Buy |
| 2015-01-27 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Cytosorbents Corp (CTSO) 最新ニュース
Cytosorbents Corporation (CTSO) Stock Price, News, Quote & History - Yahoo! Finance Canada
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care - PR Newswire
Cytosorbents Corporation (CTSO) stock price, news, quote and history - Yahoo Finance UK
CytoSorbents regains Nasdaq $1.00 minimum bid compliance; MVLS shortfall remains under review - TradingView
Nasdaq keeps CytoSorbents (NASDAQ: CTSO) on watch after $1 bid price return - Stock Titan
CytoSorbents regains Nasdaq minimum bid price compliance - Investing.com
CytoSorbents Regains Compliance With Nasdaq Minimum Bid Price Requirement - Moomoo
Cytosorbents Corp (CTSO) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (CTSO) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (CTSO) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (HQE) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (HQE) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
CEO Phillip Chan Buys 3,774 Shares of CytoSorbents Corp (CTSO) - GuruFocus
Cytosorbents president & COO Vincent Capponi buys $12,536 in stock By Investing.com - Investing.com Australia
Cytosorbents CEO Phillip Chan buys $22,644 in common stock - Investing.com
Cytosorbents (CTSO) CEO adds to stake in open-market buy - Stock Titan
Cytosorbents president & COO Vincent Capponi buys $12,536 in stock - Investing.com
Cytosorbents (CTSO) director buys shares in open-market trades without a preset plan - Stock Titan
Cytosorbents (CTSO) COO adds shares in open‑market buy - Stock Titan
CytoSorbents at H.C. Wainwright conference: breakeven, drug hopes - Investing.com
CytoSorbents Corp (STU:HQE) Stock Price & 30 Year Financial Data - GuruFocus
CytoSorbents to present at H.C. Wainwright conf... - Pluang
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 By Investing.com - Investing.com South Africa
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 - Investing.com
Cytosorbents Corp (CTSO) CEO bought more shares in the open market, adding to his stake - Stock Titan
CytoSorbents Corp (STU:HQE) Stock Earnings Transcripts - GuruFocus
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - easternprogress.com
CytoSorbents to present at Moody Capital Soluti... - Pluang
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - The Globe and Mail
CytoSorbents Plans 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing - citybiz
CytoSorbents to implement 1-for-20 reverse stoc... - Pluang
CytoSorbents Announces Reverse Stock Split - Morningstar
CTSO Looks 61.4% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
CytoSorb reduces severe bleeding by 37% in urge... - pluang.com
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings - Yahoo Finance
Cytosorbents Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents (CTSO) Chart: Finishes 20.35% Higher at $0.37 for the Current Session; Market Levels: Traders Can Monitor the $0.35-$0.39 Range in the Current UpdateMerger Arbitrage - dars.gov.et
Cytosorbents (CTSO) Shares: Finishes 5.62% Higher at $0.38; Levels: Support at $0.36 and Resistance at $0.40 Frame the Range on the DayDividend Stock Picks - careplusvn.com
Cytosorbents (CTSO) Financial Update: EPS Comes in Below Forecast; Market Follow-Through: Shares Finish 4.56% LowerEarnings Season Outlook - vinanet.vn
CTSO: CytoSorbents Future Value Drivers Support Price Target of $4.00 - Yahoo Finance
CytoSorbents (CTSO) wins approval for reverse split and director slate at 2026 meeting - Stock Titan
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Cytosorbents Corp. R (HQE1.DU) Q1 FY2026 earnings call transcript - Yahoo Finance
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Cytosorbents Corp Earnings Call Transcript - GuruFocus
Cytosorbents Corp (CTSO) Stock News Today - TradingKey
CytoSorbents posts $9.6M Q2 revenue, narrows cash burn and advances DrugSorb-ATR regulatory path - TradingView
Cytosorbents Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nea - GuruFocus
Is CytoSorbents Corp (CTSO) a Value Opportunity After Q2 Earning - GuruFocus
Cytosorbents Corp (CTSO) 財務データ
収益
当期純利益
現金流量
EPS
Cytosorbents Corp (CTSO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Capponi Vincent | President and COO |
Sep 14 '26 |
Buy |
6.05 |
2,073 |
12,537 |
40,387 |
| Sobel Alan D. | Director |
Sep 15 '26 |
Buy |
6.10 |
2,500 |
15,254 |
9,887 |
| Chan Phillip P. | Chief Executive Officer |
Sep 04 '26 |
Buy |
0.35 |
200,000 |
70,000 |
1,944,432 |
| MARIANI PETER J | Chief Financial Officer |
Jun 15 '26 |
Buy |
0.44 |
100,000 |
44,000 |
638,113 |
| Chan Phillip P. | Chief Executive Officer |
Jun 12 '26 |
Buy |
0.40 |
251,136 |
100,454 |
1,734,099 |
| Chan Phillip P. | Chief Executive Officer |
Jun 15 '26 |
Buy |
0.43 |
10,333 |
4,443 |
1,744,432 |
0.47%
0.17%
大文字化:
|
ボリューム (24 時間):